프랑스 - 프랑스어 - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

arrow generiques - alginate de sodium 500 mg; bicarbonate de sodium 267 mg - suspension - 500 mg - pour un sachet > alginate de sodium 500 mg > bicarbonate de sodium 267 mg - autres medicaments pour l’ulcere peptique et le reflux gastro-oesophagien (r.g.o) - code atc : a02bx13 - classe pharmacothérapeutique : autres médicaments pour l’ulcère peptique et le reflux gastro-œsophagien (r.g.o) - code atc : a02bx13.ce médicament est indiqué dans le traitement du reflux gastro-œsophagien qui se traduit par des brûlures d’estomac (pyrosis), des remontées ou renvois acides et des aigreurs d’estomac.

미국 - 영어 - NLM (National Library of Medicine)

pharmaceutical associates, inc. - sodium citrate (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium citrate 500 mg in 5 ml - sodium citrate and citric acid oral solution usp is an effective alkalinizing agent. it is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. this product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively. sodium citrate and citric acid oral solution usp is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. this product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. patients on sodium-restricted diets or with s

미국 - 영어 - NLM (National Library of Medicine)

zila therapeutics, inc. - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - sodium fluoride 0.044 ml in 1 ml - anticavity approved uses - aids in prevention of dental caries (cavities). - the combined daily use of a fluoride preventive treatment rinse and a fluoride toothpaste can help reduce the incidence of dental cavities. warnings - please keep out of reach of children. - if more than used for rinsing is accidentally swallowed get medical help or contact a poison control center right away. use only under guidance or supervision of a dentist or doctor. directions: this is a fluoride treatment rinse, not a mouthwash.  read directions carefully before using. inactive ingredients: distilled water, monosodium phosphate, sodium benzoate, sodium saccharin, artificial color, artificial flavor. made for and distributed in us by: zila therapeutics, inc., p.o. box 3889, batesville, ar 72503 1-800-228-5595

미국 - 영어 - NLM (National Library of Medicine)

bausch health us llc - sodium phenylacetate (unii: 48n6u1781g) (phenylacetic acid - unii:er5i1w795a), sodium benzoate (unii: oj245fe5eu) (benzoic acid - unii:8skn0b0mim) - sodium phenylacetate 100 mg in 1 ml - ammonul is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. during acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see warnings and precautions (5) ]. none. risk summary available data with ammonul use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with ammonul. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pre

미국 - 영어 - NLM (National Library of Medicine)

cardinal health - sodium citrate, unspecified form (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium citrate 500 mg in 5 ml - sodium citrate and citric acid oral solution usp is an effective alkalinizing agent. it is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. this product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively. sodium citrate and citric acid oral solution usp is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. this product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. patients on sodium-restricted diets or with s

미국 - 영어 - NLM (National Library of Medicine)

braintree laboratories, inc. - sodium sulfate (unii: 0ypr65r21j) (sodium cation - unii:lyr4m0nh37), potassium sulfate (unii: 1k573lc5tv) (potassium cation - unii:295o53k152), magnesium sulfate, unspecified form (unii: de08037sab) (magnesium cation - unii:t6v3lhy838) - sodium sulfate 17.5 g in 1 ml - suprep bowel prep kit is indicated for cleansing of the colon as a preparation for colonoscopy in adult and pediatric patients 12 years of age and older. suprep bowel prep kit is contraindicated in the following conditions: - gastrointestinal obstruction or ileus  [see warnings and precautions ( 5.6)] - bowel perforation [see warnings and precaution ( 5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any of the ingredients in suprep bowel prep kit risk summary there are no available data on suprep bowel prep kit use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproductive studies have not been conducted with sodium sulfate, potassium sulfate, and magnesium sulfate (suprep bowel prep kit). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies

미국 - 영어 - NLM (National Library of Medicine)

par pharmaceutical, inc. - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 0.94 g in 1 g - sodium phenylbutyrate powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of the dosage and administration section.) previously, neona

미국 - 영어 - NLM (National Library of Medicine)

sigmapharm laboratories, llc - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 0.94 g in 1 g - sodium phenylbutyrate powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of t

미국 - 영어 - NLM (National Library of Medicine)

mayne pharma inc - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - fluoride ion 0.5 mg in 1 ml - it has been established that ingestion of fluoridated drinking water (1 ppm f) during the period of tooth development results in significant decrease in the incidence of dental caries. sodium fluoride drops 0.5 mg were developed to provide systemic fluoride for use as a supplement in pediatric patients from 6 months to age 3 and older, living in areas where the drinking water fluoride level does not exceed 0.6 ppm f. do not use in areas where drinking water exceeds 0.6 ppm f. do not administer to pediatric patients less than 6 months old.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.